Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TBXU | 46.16 | 0.68 | +1.49% |
| Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU) | |||
| FLQL | 73.90 | 0.46 | +0.63% |
| Franklin U.S. Large Cap Multifactor Index ETF (FLQL) | |||
| JUNT | 37.55 | 0.04 | +0.10% |
| AllianzIM U.S. Equity Buffer10 Jun ETF (JUNT) | |||
| BSR | 29.24 | N/A | N/A |
| Beacon Unified Catalyst ETF (BSR) | |||
| JPIN | 73.44 | -0.94 | -1.26% |
| JPMorgan Diversified Return International Equity ETF (JPIN) | |||
A.I.dvisor indicates that over the last year, BMA has been closely correlated with GGAL. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMA jumps, then GGAL could also see price increases.
| Ticker / NAME | Correlation To BMA | 1D Price Change % | ||
|---|---|---|---|---|
| BMA | 100% | -0.40% | ||
| GGAL - BMA | 91% Closely correlated | -1.54% | ||
| BBAR - BMA | 90% Closely correlated | -1.40% | ||
| SUPV - BMA | 88% Closely correlated | -1.05% | ||
| BSAC - BMA | 50% Loosely correlated | N/A | ||
| NU - BMA | 50% Loosely correlated | +2.47% | ||
More | ||||
| Ticker / NAME | Correlation To BMA | 1D Price Change % |
|---|---|---|
| BMA | 100% | -0.40% |
| BMA (4 stocks) | 98% Closely correlated | +0.19% |
| Banks (430 stocks) | 35% Loosely correlated | +1.12% |
| Regional Banks (357 stocks) | 31% Poorly correlated | +1.28% |
a regional bank
Industry RegionalBanks
BMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 36 cases where BMA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMA's RSI Oscillator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMA advanced for three days, in 235 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMA as a result. In 65 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for BMA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 28 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for BMA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock better than average.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BMA's P/B Ratio (0.001) is slightly lower than the industry average of (1.262). P/E Ratio (0.001) is within average values for comparable stocks, (13.479). Projected Growth (PEG Ratio) (0.520) is also within normal values, averaging (1.190). Dividend Yield (0.033) settles around the average of (0.035) among similar stocks. BMA's P/S Ratio (1.824) is slightly lower than the industry average of (3.738).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. BMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.